ν λͺ¨μ‘Έλ‘λ§μ΄λ
ν λͺ¨μ‘Έλ‘λ§μ΄λλ μμ μ’ μνμμ μ¬μ©λλ κ²½κ΅¬μ© μν¬ν νμ’ μμ μ λλ€. μλΉ μ°κ΅¬μ λ°λ₯΄λ©΄ μ£Όλ‘ λ°λ €κ²¬μ λ¦Όνμ’ , νμμ’ λ° μ κ²½κ΅μ’ μΉλ£μ νκ°λμμ΅λλ€. > **κ²½κ³ **: ν λͺ¨μ‘Έλ‘λ§μ΄λλ κ°λ ₯ν **μΈν¬λ μ± μ½λ¬Ό**μ λλ€. μ격ν ννμλ² μμ λ° μ·¨κΈ μ§μΉ¨μ λ°λΌ νλ ¨λ μ λ¬Έκ°λ§μ΄ μ€λΉνκ³ ν¬μ¬ν΄μΌ ν©λλ€.
μμ© κΈ°μ : Temozolomide acts as an **oral alkylating agent**. It undergoes rapid chemical conversion at physiologic pH to the active compound, MTIC. **Mechanism of Action**: Alkylates/methylates DNA (most often at the **N-7 or O-6 positions of guanine residues**) β DNA methylation β DNA damage β **Cell death** (apoptosis).
λλ¬Ό μ’ λ³ μ©λ
- Lymphoma, melanoma, and gliomas Β· 60-65 mg/m2 Β· PO Β· q24h Β· for 5 consecutive days on a monthly basis (28 days) for 4 to 6 cycles
- Relapsed lymphoma Β· 100 mg/m2 Β· PO Β· q24h Β· for 5 consecutive days every 2 weeks
- Not advised Β· Not advised Β· PO Β· Not advised based on early toxicity studies.
μ©λμ λ©΄ν μμ μ λ¬Έκ°λ₯Ό μν μμ μ°Έκ³ μλ£μ λλ€. νμ μ΅μ λΌλ²¨κ³Ό κ°λ³ νμμ λν΄ νμΈνμμμ€.
ν¬μ¬ κ²½λ‘
κΈκΈ°
- Known hypersensitivity to temozolomide
- Pre-existing bone marrow suppression
μ΄μλ°μ
- Myelosuppression (bone marrow suppression)
- Gastrointestinal toxicity (vomiting, diarrhea, anorexia)
- Lethargy
- Polydipsia
- Altered renal parameters
- Altered hepatic parameters
λͺ¨λν°λ§
- Complete Blood Count (CBC) prior to each cycle and at nadir
- Renal function panel
- Hepatic function panel
- Clinical signs of GI toxicity or lethargy
κ³Όμ©λ
**Overdose** may lead to severe and potentially fatal **myelosuppression** (pancytopenia) and severe **gastrointestinal toxicity**. * **Treatment**: There is no specific antidote. Treatment is strictly supportive, including broad-spectrum antibiotics for neutropenia, blood transfusions if necessary, and aggressive antiemetic/fluid therapy.
VetSheet μ½λ¬Ό λ νΌλ°μ€λ λ©΄ν μμ μ λ¬Έκ°λ₯Ό μν μμ μμ¬κ²°μ 보쑰 λꡬμ΄λ©°, μ λ¬Έμ νλ¨μ΄λ μ μ‘°μ¬μ μ΅μ λΌλ²¨μ λμ νμ§ μμ΅λλ€.